Friedrich L., Kikuchi Y., Matsuda Y., Binder U., Skerra A. (2022) Efficient secretory production of proline/alanine/serine (PAS) biopolymers in Corynebacterium glutamicum yielding a monodisperse biological alternative to polyethylene glycol (PEG). Microb. Cell. Fact. 21, 227.

⇒ Full text

Schilz J., Clement C., Greiner F., Skerra A. (2022) Direct affinity purification of long-acting PASylated proteins with therapeutic potential using L-prolinamide for mild elution. Angew. Chem. Int. Ed. Engl. 61, e202200079.

⇒ Full text

Schilz J., Binder U., Friedrich L., Gebauer M., Lutz C., Schlapschy M., Schiefner A., Skerra A. (2021) Molecular recognition of structurally disordered Pro/Ala-rich sequences (PAS) by antibodies involves an Ala residue at the hot spot of the epitope. J. Mol. Biol. 433, 167113.

⇒ Full text

Binder U., Skerra A. (2020) PASylated Thymosin α1: a long-acting immunostimulatory peptide for applications in oncology and virology. Int. J. Mol. Sci. 22, E124.

⇒ Abstract

Schiefner A., Walser R., Gebauer M., Skerra A. (2020) Proline/alanine-rich sequence (PAS) polypeptides as an alternative to PEG precipitants for protein crystallization. Acta Cryst. F76, 320-325.

⇒ Abstract

Richter A., Knorr K., Schlapschy M., Robu S., Morath V., Mendler C., Yen H., Steiger K., Kiechle M., Weber W., Skerra A., Schwaiger M. (2020) First in-human medical imaging with a PASylated 89Zr-labeled anti-HER2 Fab-fragment in a patient with metastatic breast cancer. Nucl. Med. Mol. Imaging 54, 114–119.

⇒ Abstract

Powers N. E., Swartzwelter B., Marchetti C., de Graaf D. M., Lerchner A., Schlapschy M., Datar R., Binder U., Edwards C. K. 3rd, Skerra A., Dinarello C. A. (2019) PASylation of IL-1 Receptor antagonist (IL-1Ra) retains IL-1 blockade and extends its duration in mouse urate crystal-induced peritonitis. J. Biol. Chem. 295, 868 –882.

⇒ Abstract

Griffiths K., Binder U., McDowell W., Tommasi R., Frigerio M., Darby W.G., Hosking C.G., Renaud L., Machacek M., Lloyd P., Skerra A., Foley M. (2019) Half-life extension and non-human primate pharmacokinetic safety studies of i-body AD-114 targeting human CXCR4. MAbs 11, 1331-1340.
⇒ Abstract

Längin M., Mayr T., Reichart B., Michel S., Buchholz S., Guethoff S., Dashkevich A., Baehr A., Egerer S., Bauer A., Mihalj M., Panelli A., Issl L., Ying J., Fresch A.K., Buttgereit I., Mokelke M., Radan J., Werner F., Lutzmann I., Steen S., Sjöberg T., Paskevicius A., Qiuming L., Sfriso R., Rieben R., Dahlhoff M., Kessler B., Kemter E., Klett K., Hinkel R., Kupatt C., Falkenau A., Reu S., Ellgass R., Herzog R., Binder U., Wich G., Skerra A., Ayares D., Kind A., Schönmann U., Kaup F.J., Hagl C., Wolf E., Klymiuk N., Brenner P., Abicht J.M. (2018) Consistent success in life-supporting porcine cardiac xenotransplantation. Nature 564, 430-433.

⇒ Abstract

Xia Y., Schlapschy M., Morath V., Roeder N., Vogt E.I., Stadler D., Cheng X., Dittmer U., Sutter K., Heikenwalder M., Skerra A., Protzer U. (2018) PASylated interferon α efficiently suppresses hepatitis B virus and induces anti-HBs seroconversion in HBV-transgenic mice. Antiviral Res. 161, 134-143.

⇒ Abstract

Nganou-Makamdop K., Billingsley J.M., Yaffe Z., O’Connor G., Tharp G.K., Ransier A., Laboune F., Matus-Nicodemos R., Lerner A., Gharu L., Robertson J.M., Ford M.L., Schlapschy M., Kuhn N., Lensch A., Lifson J., Nason M., Skerra A., Schreiber G., Bosinger S.E., Douek D.C. (2018) Type I IFN signaling blockade by a PASylated antagonist during chronic SIV infection suppresses specific inflammatory pathways but does not alter T cell activation or virus replication. PLoS Pathog. 14, e1007246.

⇒ Abstract

Gebauer M. & Skerra A. (2018) Prospects of PASylation^® for the design of protein and peptide therapeutics with extended half-life and enhanced action. Bioorg. Med. Chem. 26, 2882-2887.

⇒ Abstract

Griffiths K., Habiel D. M., Jaffar J., Binder U., Darby W. G., Hosking C. G., Skerra A., Westall G. P., Hogaboam C. M., Foley M. (2018) Anti-fibrotic effects of CXCR4-targeting i-body AD-114 in preclinical models of pulmonary fibrosis. Sci. Rep. 8, 3212.

⇒ Abstract

Breibeck J. & Skerra A. (2018) The polypeptide biophysics of proline/alanine-rich sequences (PAS): Recombinant biopolymers with PEG-like properties. Biopolymers 108, e23069.

⇒ Abstract

Binder U. & Skerra A. (2017) PASylation^®: A versatile technology to extend drug delivery. Curr. Opin. Colloid Int. 31, 10-17.

⇒ Abstract

Kuhn N., Schmidt C. Q., Schlapschy M., Skerra A. (2016) PASylated Coversin, a C5-specific complement inhibitor with extended pharmacokinetics, shows enhanced anti-hemolytic activity in vitro. Bioconjug. Chem. 27, 2359-2371.

⇒Abstract

Bolze F., Morath V., Bast A., Rink N., Schlapschy M., Mocek S., Skerra A., Klingenspor M. (2015) Long-acting PASylated leptin ameliorates obesity by promoting satiety and preventing hypometabolism in leptin-deficient Lep^ob/obmice. Endocrinology 157, 233–244.

⇒ Abstract

Morath V., Bolze F., Schlapschy M., Schneider S., Sedlmayer F., Seyfarth K., Klingenspor M., Skerra A. (2015) PASylation of murine leptin leads to extended plasma half-life and enhanced in vivo efficacy. Mol. Pharmaceutics 12, 1431–1442.

⇒ Abstract

Mendler C. T., Friedrich L., Laitinen I., Schlapschy M., Schwaiger M., Wester H.J., Skerra A. (2015) High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation. MAbs 7, 96-109.

⇒ Abstract

Harari D., Kuhn N., Abramovich R., Sasson K., Zozulya AL., Smith P., Schlapschy M., Aharoni R., Köster M., Eilam R., Skerra A., Schreiber G. (2014) Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosis. J. Biol. Chem. 289, 29014-29029.

⇒ Abstract

Di Cesare S., Binder U., Maier T., Skerra A. (2013) High-yield production of PASylated human growth hormone using secretory E. coli technology. BioProcess Int. 11, 30–38.

⇒ Abstract